Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
Regenxbio Inc (RGNX) is a clinical-stage biotechnology leader advancing novel AAV gene therapies through its proprietary NAV® technology platform. This page provides investors and stakeholders with centralized access to the company’s latest press releases, clinical trial updates, and strategic developments.
Track critical updates across Regenxbio’s pipeline, including progress on RGX-202 for Duchenne muscular dystrophy, RGX-121 for Hunter syndrome, and ABBV-RGX-314 for retinal diseases. Stay informed about regulatory milestones, manufacturing advancements, and partnership announcements with entities like AbbVie.
All content is sourced directly from Regenxbio’s official communications, ensuring accuracy and timeliness. Bookmark this page for streamlined access to essential updates on one-time gene therapies targeting rare genetic disorders.
REGENXBIO (Nasdaq: RGNX) announced a leadership transition effective July 1, 2024. Curran Simpson, currently COO, will become President, CEO, and Board member. Co-Founder Kenneth T. Mills steps down as CEO but will assume the Chairman role. Daniel Tassé is appointed Lead Independent Director. Simpson, a veteran executive, has been with REGENXBIO since 2015, overseeing key business functions. The company reiterated its financial guidance, expecting $380.5 million in cash to fund operations into 2026, excluding potential milestone payments from AbbVie and monetization of a review voucher.
REGENXBIO (Nasdaq: RGNX) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 12, 2024, at 8:00 a.m. EDT in Miami, FL. The event will feature a fireside chat, accessible via live webcast on REGENXBIO's website, with an archived replay available for 30 days post-event.
REGENXBIO Inc. (Nasdaq: RGNX) will participate in upcoming investor conferences including the BofA Securities Health Care Conference and the Stifel Tailoring Genes Genetic Medicines Forum. The events will feature fireside chats and webcasts accessible through the company's website.
REGENXBIO reported its first quarter 2024 financial results and recent operational highlights, showcasing progress towards BLA filing in 2024 and pivotal trial initiations for Duchenne and diabetic retinopathy. The company announced positive interim efficacy and safety data, cash reserves of $381 million, and planned meetings with the FDA. Program highlights include advancements in neuromuscular and retinal diseases. Financially, revenues decreased to $15.6 million, with increased cash position but higher R&D and G&A expenses leading to a net loss of $63.3 million.
REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results and operational highlights. Listeners can register for the webcast to participate in the Q&A session. A replay will be available on the investor website.
FAQ
What is the current stock price of Regenxbio (RGNX)?
What is the market cap of Regenxbio (RGNX)?
